



Microvascular decompression for trigeminal neuralgia in the elderly: efficacy and safety

Tobias Greve¹ · Joerg-Christian Tonn¹ · Jan-Hinnerk Mehrkens¹

Received: 14 July 2020 / Revised: 15 August 2020 / Accepted: 24 August 2020 / Published online: 30 August 2020
© The Author(s) 2020

Abstract

Objective The safety and efficacy of surgical microvascular decompression (MVD) in elderly patients with trigeminal neuralgia (TN) is controversially discussed in the literature. A widespread reluctance to expose this cohort to major intracranial surgery persists. Our aim was to compare the efficacy and safety between older and younger patients with TN.

Methods In this cross-sectional study, 139 MVD procedures (103 patients < 70 and 36 patients ≥ 70) were included. Surgical fitness was assessed by the American Society of Anesthesiology (ASA) grade. The pain-free interval was evaluated using Kaplan–Meier analysis only in patients with a recent follow-up visit. Independent risk factors for recurrence in patients with a minimum 12-month follow-up were determined.

Results Patients ≥ 70 showed a significantly higher number of comorbidities. Pain intensity, affection of trigeminal branches and symptom duration was similar between groups. No significant difference in treatment associated complications and permanent neurological deficits was shown. There was no treatment-related mortality. A tendency towards a lower recurrence rate in patients < 70 did not reach statistical significance (17.6% vs. 28.6%, $P=0.274$). Pain-free interval was not different between both cohorts (78.7 vs. 73.5 months, $P=0.391$).

Conclusion Despite a higher prevalence of comorbidities in elderly patients, complication rates and neurological deficits after MVD were comparable to younger patients. Rates of immediate and long-term pain relief compared favorably to previous studies and were similar between elderly and younger patients. These data endorse MVD as a safe and effective first-line surgical procedure for elderly patients with TN and neurovascular conflict on MRI.

Keywords Efficacy · Elderly · Microvascular decompression · Safety · Trigeminal neuralgia

Introduction

Classical trigeminal neuralgia (TN) is a chronic pain disorder manifesting with unilateral paroxysmal stabbing pain involving one or more divisions of the trigeminal nerve. It is the most prevalent facial pain syndrome and pain onset is usually between the ages of 40 and 60. Pain severity can hinder activities of daily living and impairs quality of life [26].

Anticonvulsant medication is the first-line therapy and can reduce TN pain intensity in 75% of patients [10]. However, the efficacy of conservative treatment generally decreases over time and TN is frequently resistant to multi-drug treatment regimens. Also, these medications commonly

induce side effects that lead to discontinuation of the medical therapy [39].

Around 75% of TN cases are associated with trigeminal nerve compression by a branch of the superior cerebellar artery or other blood vessels [2, 8, 12]. In cases where such a neurovascular conflict is present and where other underlying etiologic conditions such as demyelinating autoimmune diseases are ruled out, microvascular decompression of the trigeminal nerve (MVD) is the primary surgical treatment option since it is the only causal treatment for TN and offers a high rate of immediate and long-term pain relief [14, 15].

Although MVD is widely offered to younger patients, neurosurgeons tend to be reluctant to offer MVD to elderly patients, primarily because of concerns regarding complications of general anesthesia and posterior fossa surgery [3, 19, 21, 31].

However, the incidence of TN increases with age, with 4.1 per 100,000 per year in the general population [9, 20]

✉ Tobias Greve
tobias.greve@med.uni-muenchen.de

¹ Department of Neurosurgery, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

and 20 per 100,000 per year in patients above 65 years [1]. Antiepileptic drugs used to treat TN induce side effects more frequently in elderly patients [39] and these patients are generally more sensitive to disturbances of the central nervous system, which can result in gait disturbances and ataxia and an increased tendency to fall [34]. In addition to possible comorbidities, there are physiological changes during aging, which render the serum concentration of antiepileptic drugs unpredictable [29]. One study found 25% of patients taking more than one drug were possible candidates for drug–drug interactions in the geriatric cohort [37]. Older patients are more often offered symptomatic surgical therapies such as percutaneous balloon compression [4] or radiofrequency rhizotomy [17] which access the gasserian ganglion via the oval foramen and circumvent the need for major intracranial neurosurgery. These symptomatic surgical options are however associated to poorer long-term pain control compared to MVD [24].

A higher incidence of TN in the elderly and the above-mentioned clinical particularities in this cohort combined with an overall ageing society [7] warrant a new perspective on MVD for patients in the senium.


The purpose of this study was to analyze the neurological outcome and TN recurrence rates in patients beyond 70 years of age in comparison to younger patients to add more definitive data to the mixed reports on that topic.

Methods

Study design

In this single-center cross-sectional study, we reviewed the medical records of 485 consecutive patients undergoing surgical procedures to treat trigeminal neuralgia between 01/2012 and 02/2020. Patients who only received radiofrequency rhizotomy and who previously received MVD were excluded. Absence of a neurovascular conflict on MRI, presence of tumors within the proximity of the trigeminal nerve and presence of demyelinating autoimmune diseases were excluded. Whether the neurovascular conflict was specific to the root entry zone or whether the nerve showed atrophy was not evaluated. Consequently, a possible change in outcome depending on these MRI parameters was not part of the study. To comply with the cross-sectional design of the study, all remaining patients were actively contacted and only those who were followed up within 4 weeks of the study end (database closure 03/2020) were included. By this means, 139 MVD procedures (equaling 139 patients) were included (Fig. 1). The study duration for each patient ended upon recurrence or with the most recent follow-up. The local ethics committee board approved this cross-sectional analysis (approval number 20-233). Patient consent was waived for this study. Patients younger than 70 years of age at

Fig. 1 Schematic overview of patient inclusion and exclusion



surgery (termed thereafter “patients < 70”) and patients that were 70 years or older (termed thereafter “patients ≥ 70”) were compared using.

Preoperative decision-making and operative technique

All patients < 70 with TN and a visible neurovascular conflict were recommended to undergo MVD when conservative management was insufficient to control pain or when significant side effects of the medication were reported. In patients < 70 who showed relevant comorbidities, who did not show a neurovascular conflict or who had a history of an inflammatory demyelinating disease, radiofrequency rhizotomy was recommended as an alternative surgical option for TN.

Patients ≥ 70 were routinely recommended radiofrequency rhizotomy but were also offered to undergo MVD when American Society of Anesthesiology (ASA) grade was 3 or less.

Microvascular decompression was performed via a retrosigmoid approach with the patient in a modified park bench position. Intraoperative monitoring was performed in all cases. Patients were usually seen in the outpatient clinic for the first follow-up examination after 3 months.

Analysis and outcome definitions

TN disease variables included degree of pain intensity measured by the numerical rating scale (NRS) [13, 23], degree of pain control with/without medication measured by the Barrow Neurological Institute Pain Intensity (BNI) Score [30], TN medication regimen before MVD and duration of TN symptoms before MVD. The operative fitness status was assessed by the ASA grade [11] and by identifying comorbidities.

Postoperative data included length of hospital stay, presence of neurologic deficits, pain intensity before and after MVD, oral pain medication before MVD and after MVD, complications and subsequent TN procedures. Pain intensity was determined at the first follow-up and at the most recent follow-up visit or most recent follow-up telephone interview using NRS rating and BNI Score.

Statistics

We used Fisher’s exact test and Chi-square test with Yates correction to compare distribution of categorical variables among groups. Continuous variables were tested for normal distribution using the Shapiro–Wilk test and no continuous variable was found to be normally distributed. Consequently, we employed Mann–Whitney *U* test to compare continuous variables.

Long-term pain intensity and outcome were only performed in patients who either suffered a recurrence or who had a follow-up period of at least 12 months. Long-term outcome was evaluated by Kaplan–Meier analysis with log-rank testing to compare the pain-free interval between groups. Binary logistic regression analysis was employed to find factors associated with recurrence. Statistical significance was set at $P < 0.05$. All statistical analyses were performed using SPSS version 25 (IBM).

Results

Demographics and characterization of trigeminal neuralgia

Of 139 patients with TN who received an MVD, 103 (74.1%) were younger than 70 years and 36 (25.9%) were 70 years or older. The age difference was statistically different as per definition of both patient cohorts ($P < 0.001$). Absolute numbers of risk factors for TN like additive headache syndromes, chronic sinusitis or previous sinus surgery were low and similar in both groups. There was a significantly higher proportion of hypercholesterolemia, arterial hypertension, carotid stenosis, and history of cancer in patients ≥ 70. Other comorbidities were not different between groups (Table 1). As a composite score of preoperative comorbidities, the above-mentioned differences reflected in the ASA status. Patients ≥ 70 had a higher frequency of an ASA status of 3 ($P = 0.034$). No patients with an ASA status of 4 or 5 underwent MVD.

Distribution of affected branches of the trigeminal nerve was similar. Median pain intensity before MVD was 7 on the NRS in both groups. The BNI Score was 4 and 5, in 50% of patients respectively (no group difference, $P = 0.845$) (Table 2).

Before MVD, 97.1% of patients received oral medication, the most prevalent substance being carbamazepine. Four patients were not on oral medication due to severe side effects leading to discontinuation (4 patients < 70 and 1 patient ≥ 70, $P = 0.876$).

Treatment details and safety analysis

Most patients underwent MVD as primary surgical treatment option (96.1% in patients < 70 versus 86.2% in patients ≥ 70, $P = 0.036$), while a small percentage received MVD after failed radiofrequency rhizotomy. The median length of surgery and hospital stay was similar in both groups (Table 2).

Overall rates of transient neurological deficits were low in both groups, with transient mild facial hypoesthesia making up most of these deficits (23/139, 16.5%). Two patients < 70 required surgical revision due to deep but extradural wound

Table 1 Patient demographics and comorbidities

Group	< 70 years	≥ 70 years	Overall	<i>P</i>
<i>N</i>	103	36	139	
Age (years)	57.6 [46.8–65.2]	73.4 [71.9–75.3]	63.4 [51.8–71.1]	< 0.001
Sex (females)	51 (49.5%)	17 (47.2%)	68 (48.9%)	0.813
ASA status				0.034
1	6 (5.8%)	–	6 (4.3%)	
2	82 (79.6%)	26 (72.2%)	108 (77.7%)	
3	15 (14.6%)	10 (27.8%)	25 (18%)	
Comorbidities				
Headache syndrome	7 (6.8%)	2 (5.6%)	9 (6.5%)	0.795
Surgery on sinuses	6 (5.8%)	–	6 (4.3%)	0.139
Fibromyalgia	4 (3.9%)	–	4 (2.9%)	0.230
Chronic sinusitis	1 (1.0%)	–	1 (0.7%)	0.553
Hypercholesterolemia	2 (1.9%)	7 (19.4%)	9 (6.5%)	0.001
Arterial hypertension	32 (31.1%)	18 (50.0%)	50 (36.0%)	0.042
Obstructive sleep apnea	5 (4.9%)	1 (2.8%)	6 (4.3%)	0.690
Anticoagulation	2 (1.9%)	2 (5.6%)	4 (2.9%)	0.572
Carotid stenosis	2 (1.9%)	6 (16.7%)	8 (5.8%)	0.004
TIA in the past	3 (2.9%)	1 (2.8%)	4 (2.9%)	0.967
Cardiac stents, aspirin	5 (4.9%)	7 (19.4%)	12 (8.6%)	0.013
Diabetes mellitus type 2	4 (3.9%)	2 (5.6%)	6 (4.3%)	0.671
Nicotine abuse	11 (10.7%)	–	11 (7.9%)	0.066
Von Willebrand disease	1 (1.0%)	–	1 (0.7%)	1.000
GERD	2 (1.9%)	–	2 (1.4%)	0.613
Hypothyroidism	10 (9.7%)	8 (22.2%)	18 (12.9%)	0.080
Depression	4 (3.9%)	0 (0%)	4 (2.9%)	0.572
History of cancer	1 (1%)	6 (16.7%)	7 (5%)	0.001

Bold text indicates a statistically significant difference

Frequencies are presented as *n* (%). Age is presented as median and interquartile range

ASA American Society of Anesthesiologist grading system of operative fitness, TIA transient ischemic attack, GERD gastroesophageal reflux disease

infection. No other surgical revisions were required. The combined count of short-term neurological deficits and treatment related complications was not different between groups (Table 3).

As to long-term neurological deficits, moderate postoperative hearing impairment occurred in 2 patients < 70 and 1 patient ≥ 70. Facial hypoesthesia improved over time in all patients but a small area of permanent hypoesthesia persisted in 6 patients (4 patients < 70 and 2 patients ≥ 70). Persistent chronic headache after MVD was found in one patient of each group. One patient < 70 has persistent severe vertigo, incapacitating the patient from engaging in gainful employment. The rate of persistent neurological deficits was not different for

patients < 70 and patients ≥ 70 (Table 3). There was no treatment related mortality.

Efficacy and long-term follow-up

Of all patients, 133 (95.7%) reported immediate pain relief after surgery with no significant difference between groups ($P = 0.649$) (Table 2).

The median follow-up for all patients was 25.2 months, with no significant difference between groups (Table 4).

At first follow-up after 3 months, 131 (94.2%) patients were pain free, with 19 of them still on a residual dose of anticonvulsant medication. Five patients (3.6%) had a good effect with occasional pain that did not reduce quality of

Table 2 Disease characteristics and treatment

Group	< 70 years	≥ 70 years	Overall	<i>P</i>
<i>N</i>	103	36	139	
Trigeminal branch affected				0.525
II	26 (25.2%)	7 (19.4%)	33 (23.7%)	
III	14 (13.6%)	8 (22.2%)	22 (15.8%)	
I + II	7 (6.8%)	4 (11.1%)	11 (7.9%)	
II + III	42 (40.8%)	16 (44.4%)	58 (41.7%)	
I + II + III	14 (13.6%)	1 (2.8%)	15 (10.8%)	
Side				0.401
Left	45 (43.7%)	14 (38.9%)	59 (42.4%)	
Right	58 (56.3%)	22 (61.1%)	80 (57.6%)	
Symptom duration before treatment (years)	4.0 [2.0–8.0]	4.5 [2.4–9.3]	4.0 [2.0–8.0]	0.442
Pain intensity before MVD, NRS	8 [7–8]	7 [7–8]	7 [7–8]	0.332
Pain intensity before MVD, BNI				0.845
BNI Score 4	51 (49.5%)	19 (52.8%)	70 (50.4%)	
BNI Score 5	52 (50.5%)	17 (47.2%)	69 (49.6%)	
MVD primary therapy	99 (96.1%)	31 (86.2%)	130 (93.5%)	0.036
MVD on recurrence after radiofrequency rhizotomy	4 (3.9%)	5 (13.8%)	9 (6.5%)	
Average length of surgery (minutes)	165 [147–199]	173 [138–205]	168 [144–201]	0.579
Average length of stay (days)	8.3 [8.1–9.9]	9.1 [8.2–10.1]	8.4 [8.1–9.9]	0.225
Immediate pain relief after MVD	99 (96.1%)	34 (94.4%)	133 (95.7%)	0.649

Bold text indicates a statistically significant difference

Frequencies are presented as *n* (%). Symptom duration, pain intensity before MVD (NRS), average length of surgery and average length of stay are presented as median and interquartile range

MVD microvascular decompression, NRS Numerical Rating Scale, BNI Score Barrow Neurological Institute Pain Intensity Score

Table 3 Complications and neurological deficits

Group	< 70 years	≥ 70 years	Overall	<i>P</i>
<i>N</i>	103	36	139	
Combined short-term complications and morbidities	22 (21.4%)	10 (27.8%)	32 (23.0%)	0.431
Transient facial numbness	16 (15.5%)	7 (19.4%)	23 (16.5%)	
Transient trochlear nerve palsy	–	1 (2.8%)	1 (0.7%)	
Transient vocal cord palsy	–	1 (2.8%)	1 (0.7%)	
Transient facial palsy after ischemia in the facial motor nucleus	–	1 (2.8%)	1 (0.7%)	
Venous sinus thrombosis with prolonged anticoagulation	1 (1%)	–	1 (0.7%)	
Cerebellar ischemia, prolonged SIADH	1 (1%)	–	1 (0.7%)	
CSF leak, lumbar drain	2 (1.9%)	–	2 (1.4%)	
Wound infection requiring surgical revision	2 (1.9%)	–	2 (1.4%)	
Surgical revision for other reasons	–	–	–	
Combined persistent deficits	8 (7.8%)	4 (11.1%)	12 (8.6%)	0.539
Persistent chronic headache	1 (1.0%)	1 (2.8%)	2 (1.4%)	
Persistent severe vertigo	1 (1.0%)	–	1 (0.7%)	
Persistent hearing impairment	2 (1.9%)	1 (2.8%)	3 (2.2%)	
Persistent facial hypesthesia	4 (3.9%)	2 (5.6%)	6 (4.3%)	
Treatment-related mortality	–	–	–	1.000

Frequencies are presented as *n* (%)

SIADH syndrome of inappropriate antidiuretic hormone secretion, CSF Cerebrospinal fluid leak

Table 4 Short- and long-term follow-up

Group	< 70 years	≥ 70 years	Overall	<i>P</i>
All patients, <i>N</i>	103	36	139	
Length of follow-up (months)	24.0 [4.2–45.8]	34.4 [8.2–71.4]	25.2 [6.0–47.2]	0.066
Pain intensity first follow-up				0.579
BNI Score 1	81 (78.6%)	31 (86.1%)	112 (80.6%)	
BNI Score 2	5 (4.9%)	0 (0%)	5 (3.6%)	
BNI Score 3	15 (14.6%)	4 (11.1%)	19 (13.7%)	
BNI Score 4	2 (1.9%)	1 (2.8%)	3 (2.2%)	
BNI Score 5	–	–	–	
Patients with ≥ 12 months follow-up, <i>N</i>	74	28	102	
Length of follow-up (months)	40.2 [22.7–64.1]	58.5 [36.2–81.9]	44.6 [26.7–72.3]	0.014
Recurrence	13 (17.6%)	8 (28.6%)	21 (20.6%)	0.274
Time to recurrence (months)	24.0 [15.5–28.4]	13.5 [7.7–38.4]	23.4 [9.5–28.4]	0.558
Pain intensity upon recurrence				0.897
BNI Score 1	–	–	–	
BNI Score 2	1 (7.7%)	–	1 (4.8%)	
BNI Score 3	3 (23.1%)	2 (25%)	5 (23.8%)	
BNI Score 4	5 (38.5%)	5 (62.5%)	10 (47.6%)	
BNI Score 5	4 (30.8%)	1 (12.5%)	5 (23.8%)	
Management of recurrence				0.431
Surgically (RF)	7 (9.5%)	5 (17.9%)	12 (11.8%)	
Medically	6 (8.1%)	3 (10.7%)	9 (8.8%)	
Pain intensity in non-recurrent patients (last follow-up)				0.350
BNI Score 1	54 (88.5%)	18 (90%)	72 (88.9%)	
BNI Score 2	–	–	–	
BNI Score 3	6 (9.8%)	1 (5%)	7 (8.6%)	
BNI Score 4	1 (1.6%)	0 (0%)	1 (1.2%)	
BNI Score 5	0 (0%)	1 (5%)	1 (1.2%)	
Pain-free interval (months) (Kaplan–Meier analysis)	78.7 [70.9, 86.6]	73.5 [59.6, 87.4]	78.5 [71.4, 85.6]	0.391

Bold text indicates a statistically significant difference

Frequencies are presented as *n* (%). Length of follow-up and time to recurrence are presented as median and interquartile range. Pain-free interval is the result of Kaplan–Meier-Analysis and is presented as median and upper/lower boundaries of the 95% confidence interval

BNI Score Barrow Neurological Institute Pain Intensity Score, *RF* radiofrequency rhizotomy

life and did not require medication (equaling BNI Score 2). These patients were not counted as early recurrence. There were 3 patients (2 patients < 70 and 1 patient ≥ 70), that reported some pain, not adequately controlled with medications (BNI Score 4). The distribution of pain-control at first follow-up was similar between groups (Table 4).

For long term analysis of pain control, only patients with a minimum of 12 months follow-up were analyzed. The median follow-up was 44.6 months and patients ≥ 70 had a longer follow-up (40.2 versus 58.5 months, *P*=0.014). Within the follow-up period, there was a tendency towards higher recurrence in patients < 70 (13, 17.6%) compared to patients ≥ 70 (8, 28.6%) but the difference was not significant (*P*=0.274). Five patients suffered from severe recurrent TN, equal to a BNI Score of 5. Pain-control and severity of recurrent TN, as measured by the BNI Score was similar between

patients < 70 and ≥ 70 (*P*=0.897). Recurrences were managed surgically by radiofrequency rhizotomy in 12 (11.8%) cases and medically in 9 (8.8%) cases (*P*=0.431). There was a tendency towards earlier recurrence in patients ≥ 70 without statistically significant differences for both median time to recurrence (*P*=0.558, Table 4) and Kaplan–Meier based median pain-free interval (*P*=0.391, Fig. 2 and Table 4). Of 81 (79.4%) patients without recurrent TN at the latest follow-up visit, 79 (97.5%) were pain-free while 2 patients suffered from persistent TN inadequately controlled with medication (Table 4).




Fig. 2 Kaplan–Meier curve of the cumulative probability of non-recurrence of trigeminal neuralgia. The cumulative probability of non-recurrence is (analogously to cumulative survival in studies with death as endpoint) the probability of non-recurrence of trigeminal neuralgia at a certain postoperative day multiplied by the probability of having no recurrence in the previous postoperative period. It did not differ between patients <70 and patients \geq 70 years of age ($P=0.391$)

Table 5 Multivariate analysis

Variable	<i>P</i>	Odds ratio	95% Confidence interval
Symptom duration	0.430	1.06	[0.92–1.23]
BNI Score	0.322	1.46	[0.69–3.09]
Age	0.173	0.96	[0.91–1.02]
ASA status	0.803	0.77	[0.10–5.77]

BNI Score Barrow Neurological Institute Pain Intensity Score, *ASA* American society of anesthesiologist grading system of operative fitness

Risk factor analysis for recurrent trigeminal neuralgia

Univariate analyses for factors associated with recurrence of TN included demographic factors, comorbidities, treatment modalities, number of medications, pre- and postoperative pain intensity as well as postoperative neurological deficits.

There was a higher recurrence rate in patients with longer symptom duration before MVD, with a median symptom duration between patients with recurrence and non-recurrence of 3 years versus 7 years ($P=0.006$). TN not responsive to

medication before MVD, equaling BNI Score 5 ($P=0.049$), was also associated with a higher recurrence rate. Other parameters were not associated with a higher recurrence rate in univariate analysis.

For multivariate analysis, binary logistic regression was performed with the two variables proven to be associated to recurrence in univariate analysis (symptom duration and BNI Score) as well as with the variables age and ASA status. None of these variables proved as independent factor associated with a higher risk for TN recurrence after MVD (Table 5).

Discussion

In this cross-sectional study, patients with TN above and below age 70 were compared regarding efficacy and safety of MVD. Patients \geq 70 showed a significantly higher number of comorbidities and a higher proportion of preoperative ASA 3 status. Albeit the higher age and the higher number of comorbidities, no significant difference in treatment associated complications, permanent neurological deficits and—most importantly—in number of recurrences nor in the pain-free interval was shown (Fig. 2).

In terms of demographic factors patients were comparable to other studies [16, 31]. The reported rate of immediate pain relief—usually 80–95% in the literature [32, 41], and of recurrence rates—reported between 5 and 30% in the literature [5, 6, 22, 35], were comparable to the results of the present study, where we showed 95.7% immediate pain relief and a recurrence rate of 20.6%.

The most frequently occurring neurological deficit in our study was facial hypoesthesia, with most cases resolving completely. In 6 cases (4.3%), a small patch of facial mild hypoesthesia persisted, a rate that compares favorably to the literature [5, 36].

One large study found symptom duration to be positively correlated to TN recurrence [5], a finding that was recapitulated in this series. However, it failed to remain an independent risk factor in multivariate analysis. Consistent with this finding, it was previously shown that microstructural changes in the trigeminal nerve, as determined by diffusion tensor imaging MRI, are independent of symptom duration [25].

Most studies did not report detailed comorbidities or ASA status [16, 28, 33], and one study only included elderly patients with an ASA 1 and 2 status [3]. By contrast, almost 30% of patients \geq 70 in our study were classified as ASA 3. Albeit the clear gap in comorbidities between age groups, we report no difference in postoperative complications or permanent neurological deficits. The difference in comorbidities between groups thereby does not represent a limitation but a prerequisite to draw adequate conclusions. One large retrospective study analyzing

data from 3273 patients out of a nationwide database showed that procedure-related mortality increased with age with a mortality rate of 1.2% for patients over 75 years. However, no data for preoperative comorbidities of any kind nor ASA status was included in that analysis and there was no report on outcome [31].

Another important factor presented here is the Kaplan–Meier based pain-free interval analysis which previous studies lack [16, 18, 28, 31, 33]. We were able to show that not only the number of recurrences, but also the pain-free interval is similar between patients above and below the age of 70. This is a crucial finding since a longer pain-free interval directly translates into less disability, depression and anxiety, all of which have been unequivocally linked to TN [40].

Discussing alternative surgical treatment options, a large meta-analysis with 2163 patients showed that MVD had a lower number of recurrences compared to radiofrequency rhizotomy, reducing the risk by around 66% [24]. Other groups also showed that while pain control ranges at around 80% for MVD over the course of 10 years [32, 41], there were almost 30% recurrences after 3 years for radiofrequency rhizotomy throughout all age groups [27, 38].

The superior long-term outcome of MVD over symptomatic surgical treatment options underscores the favorable risk profile in the older patient cohort and provides another strong argument for MVD as a primary surgical treatment option.

Our study stands out due to its cross-sectional design since long-term outcome was only evaluated in patients who were followed-up within the last 4 weeks. In contrast, previous studies evaluated patients during routine visits but not in a cross-sectional sense at a recent time point [18, 33].

There are two main limitations to our study. First, the small sample size of patients ≥ 70 might render subgroup analysis less robust, especially in binary logistic regression modelling. Second, a selection bias inevitably occurs since patients ≥ 70 with severe contraindications to major intracranial surgery were directed towards radiofrequency rhizotomy or stereotactic radiosurgery. This must be considered when counseling patients towards the right treatment.

Despite these limitations, this study offers convincing new aspects that substantiate the justification of MVD in elderly patients.

Conclusion

In this study on the controversial topic of MVD in elderly patients with trigeminal neuralgia, we analyzed cohorts above and below 70 years of age with regard to efficacy and safety of MVD. We showed that MVD is equally safe and efficient despite a higher number of comorbidities in elderly

patients. There was no significant difference in immediate and long-term pain relief between age groups and recurrence rates compared favorably to reports on symptomatic surgical treatments such as radiofrequency rhizotomy. The relevance and novelty of our findings lies in the cross-sectional study design, the higher proportion of relevant preoperative comorbidities in the older age group and the Kaplan–Meier based analysis of the pain-free interval. Our study endorses MVD as routine surgical procedure for TN in elderly people as long as major contraindications to intracranial surgery are ruled out.

Author contributions Conception and design of study: TG, JM. Data acquisition: TG, JT, JM. Data analysis: TG. Drafting manuscript: TG. Critically revising manuscript: TG, JT, JM. Approval of the version of the manuscript to be published: TG, JT, JM.

Funding Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflicts of interest The author(s) declare that they have no competing interests.

Ethical approval The study was approved by the local ethics committee (approval number 20-233) and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Details that might disclose the identity of the subjects under study are omitted.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Amador N, Pollock BE (2008) Repeat posterior fossa exploration for patients with persistent or recurrent idiopathic trigeminal neuralgia. *J Neurosurg* 108:916–920
2. Antonini G, Di Pasquale A, Cruccu G, Truini A, Morino S, Saltelli G, Romano A, Trasimeni G, Vanacore N, Bozzao A (2014) Magnetic resonance imaging contribution for diagnosing symptomatic neurovascular contact in classical trigeminal neuralgia: a blinded case-control study and meta-analysis. *Pain* 155:1464–1471
3. Ashkan K, Marsh H (2004) Microvascular decompression for trigeminal neuralgia in the elderly: a review of the safety and efficacy. *Neurosurgery* 55:840–848 (**discussion 848-850**)

4. Asplund P, Blomstedt P, Bergenheim AT (2016) Percutaneous balloon compression vs percutaneous retrogasserian glycerol rhizotomy for the primary treatment of trigeminal neuralgia. *Neurosurgery* 78:421–428 (**discussion 428**)
5. Barker FG 2nd, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD (1996) The long-term outcome of microvascular decompression for trigeminal neuralgia. *N Engl J Med* 334:1077–1083
6. Breeze R, Ignelzi RJ (1982) Microvascular decompression for trigeminal neuralgia. Results with special reference to the late recurrence rate. *J Neurosurg* 57:487–490
7. Christensen K, Doblhammer G, Rau R, Vaupel JW (2009) Ageing populations: the challenges ahead. *Lancet* 374:1196–1208
8. Devor M, Amir R, Rappaport ZH (2002) Pathophysiology of trigeminal neuralgia: the ignition hypothesis. *Clin J Pain* 18:4–13
9. Edlich RF, Winters KL, Britt L, Long WB 3rd (2006) Trigeminal neuralgia. *J Long Term Eff Med Implants* 16:185–192
10. Fields HL (1996) Treatment of trigeminal neuralgia. *N Engl J Med* 334:1125–1126
11. Hackett NJ, De Oliveira GS, Jain UK, Kim JY (2015) ASA class is a reliable independent predictor of medical complications and mortality following surgery. *Int J Surg* 18:184–190
12. Haller S, Etienne L, Kovari E, Varoquaux AD, Urbach H, Becker M (2016) Imaging of neurovascular compression syndromes: trigeminal neuralgia, hemifacial spasm, vestibular paroxysmia, and glossopharyngeal neuralgia. *AJNR Am J Neuroradiol* 37:1384–1392
13. Heller GZ, Manuguerra M, Chow R (2016) How to analyze the visual analogue scale: Myths, truths and clinical relevance. *Scand J Pain* 13:67–75
14. Holste K, Chan AY, Rolston JD, Englot DJ (2020) Pain outcomes following microvascular decompression for drug-resistant trigeminal neuralgia: a systematic review and meta-analysis. *Neurosurgery* 86:182–190
15. Jannetta PJ, McLaughlin MR, Casey KF (2005) Technique of microvascular decompression. Technical note. *Neurosurg Focus* 18:E5
16. Javadpour M, Eldridge PR, Varma TR, Miles JB, Nurmikko TJ (2003) Microvascular decompression for trigeminal neuralgia in patients over 70 years of age. *Neurology* 60:520
17. Jin HS, Shin JY, Kim YC, Lee SC, Choi EJ, Lee PB, Moon JY (2015) Predictive factors associated with success and failure for radiofrequency thermocoagulation in patients with trigeminal neuralgia. *Pain Physician* 18:537–545
18. Jodicke A, Winking M, Deinsberger W, Boker DK (1999) Microvascular decompression as treatment of trigeminal neuralgia in the elderly patient. *Minim Invasive Neurosurg* 42:92–96
19. Kanpolat Y, Jho H-D, Tew JM, Brock M, Grigoryan YA (1996) Trigeminal neuralgia. *Surg Neurol* 45:406–408
20. Katusic S, Beard CM, Bergstralh E, Kurland LT (1990) Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945–1984. *Ann Neurol* 27:89–95
21. Kolluri S, Heros RC (1984) Microvascular decompression for trigeminal neuralgia. A five-year follow-up study. *Surg Neurol* 22:235–240
22. Kondo A (1997) Follow-up results of microvascular decompression in trigeminal neuralgia and hemifacial spasm. *Neurosurgery* 40:46–51 (**discussion 51–42**)
23. Kumar S, Rastogi S, Kumar S, Mahendra P, Bansal M, Chandra L (2013) Pain in trigeminal neuralgia: neurophysiology and measurement: a comprehensive review. *J Med Life* 6:383–388
24. Li Y, Yang L, Ni J, Dou Z (2019) Microvascular decompression and radiofrequency for the treatment of trigeminal neuralgia: a meta-analysis. *J Pain Res* 12:1937–1945
25. Lutz J, Thon N, Stahl R, Lummel N, Tonn JC, Linn J, Mehrkens JH (2016) Microstructural alterations in trigeminal neuralgia determined by diffusion tensor imaging are independent of symptom duration, severity, and type of neurovascular conflict. *J Neurosurg* 124:823–830
26. Nurmikko TJ, Eldridge PR (2001) Trigeminal neuralgia—pathophysiology, diagnosis and current treatment. *Br J Anaesth* 87:117–132
27. Obermann M (2010) Treatment options in trigeminal neuralgia. *Ther Adv Neurol Disord* 3:107–115
28. Ogungbo BI, Kelly P, Kane PJ, Nath FP (2000) Microvascular decompression for trigeminal neuralgia: report of outcome in patients over 65 years of age. *Br J Neurosurg* 14:23–27
29. Oomens MAEM, Forouzanfar T (2015) Pharmaceutical management of trigeminal neuralgia in the elderly. *Drugs Aging* 32:717–726
30. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL (2000) Gamma knife radiosurgery for trigeminal neuralgia: the initial experience of The Barrow Neurological Institute. *Int J Radiat Oncol Biol Phys* 47:1013–1019
31. Rughani AI, Dumont TM, Lin CT, Tranmer BI, Horgan MA (2011) Safety of microvascular decompression for trigeminal neuralgia in the elderly. *Clinical article. J Neurosurg* 115:202–209
32. Sarsam Z, Garcia-Fiñana M, Nurmikko TJ, Varma TR, Eldridge P (2010) The long-term outcome of microvascular decompression for trigeminal neuralgia. *Br J Neurosurg* 24:18–25
33. Sekula RF, Marchan EM, Fletcher LH, Casey KF, Jannetta PJ (2008) Microvascular decompression for trigeminal neuralgia in elderly patients. *J Neurosurg* 108:689–691
34. Seymour RM, Routledge PA (1998) Important drug-drug interactions in the elderly. *Drugs Aging* 12:485–494
35. Tatli M, Satici O, Kanpolat Y, Sindou M (2008) Various surgical modalities for trigeminal neuralgia: literature study of respective long-term outcomes. *Acta Neurochir* 150:243–255
36. Tomasello F, Germano A, Lavano A, Romano A, Cafarella D, Gorgoglione N, La Torre D (2020) A novel technical refinement of microvascular decompression: pain relief and complication rate in a consecutive series of patients with trigeminal neuralgia. *Oper Neurosurg (Hagerstown)* 19:226–233
37. Tulner LR, Frankfort SV, Gijzen GJ, van Campen JP, Koks CH, Beijnen JH (2008) Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. *Drugs Aging* 25:343–355
38. Ying X, Wang H, Deng S, Chen Y, Zhang J, Yu W (2017) Long-term outcome of percutaneous balloon compression for trigeminal neuralgia patients elder than 80 years: a STROBE-compliant article. *Medicine (Baltimore)* 96:e8199–e8199
39. Zakrzewska JM, Patsalos PN (2002) Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. *Pain* 95:259–266
40. Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH (2017) Evaluating the impact of trigeminal neuralgia. *Pain* 158:1166–1174
41. Zhang H, Lei D, You C, Mao BY, Wu B, Fang Y (2013) The long-term outcome predictors of pure microvascular decompression for primary trigeminal neuralgia. *World Neurosurg* 79:756–762